BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31876229)

  • 1. Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA ≥3 ng/ml.
    Chandra Engel J; Palsdottir T; Aly M; Egevad L; Grönberg H; Eklund M; Nordström T
    Scand J Urol; 2020 Feb; 54(1):1-6. PubMed ID: 31876229
    [No Abstract]   [Full Text] [Related]  

  • 2. Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms.
    Nordström T; Engel JC; Bergman M; Egevad L; Aly M; Eklund M; Palsdottir T; Grönberg H
    Eur Urol Open Sci; 2021 Feb; 24():11-16. PubMed ID: 34337490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study.
    Patel DN; Feng T; Simon RM; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Roehrborn C; Andriole GL; Freedland SJ
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):238-244. PubMed ID: 29795141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative probability of prostate cancer detection using the international prostate symptom score in a prostate-specific antigen-based population screening program in Japan.
    Kitagawa Y; Urata S; Narimoto K; Nakagawa T; Izumi K; Kadono Y; Konaka H; Mizokami A; Namiki M
    Asian Pac J Cancer Prev; 2014; 15(17):7079-83. PubMed ID: 25227794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of lower urinary tract symptoms on prostate cancer risk among Japanese men with prostate-specific antigen <10 ng/mL and non-suspicious digital rectal examination.
    Ito M; Masuda H; Kawakami S; Fujii Y; Koga F; Saito K; Yamamoto S; Yonese J; Fukui I; Kihara K
    Int J Urol; 2013 Dec; 20(12):1163-8. PubMed ID: 23521022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study.
    Palsdottir T; Nordström T; Aly M; Lindberg J; Clements M; Egevad L; Grönberg H; Eklund M
    PLoS One; 2019; 14(6):e0218280. PubMed ID: 31194822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
    Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
    J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
    Collin SM; Metcalfe C; Donovan J; Lane JA; Davis M; Neal D; Hamdy F; Martin RM
    BJU Int; 2008 Nov; 102(10):1400-6. PubMed ID: 18540932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence and severity of lower urinary tract symptoms are inversely correlated with the risk of prostate cancer on prostate biopsy.
    Cicione A; Cormio L; Cantiello F; Palumbo IM; DE Nunzio C; Lima E; Ucciero G; Carrieri G; Damiano R
    Minerva Urol Nefrol; 2017 Oct; 69(5):486-492. PubMed ID: 28124868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Finding the needle in a haystack": oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP).
    Herlemann A; Wegner K; Roosen A; Buchner A; Weinhold P; Bachmann A; Stief CG; Gratzke C; Magistro G
    World J Urol; 2017 Nov; 35(11):1777-1782. PubMed ID: 28516315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
    Kramer JJ; Gu L; Moreira D; Andriole G; Csizmadi I; Freedland SJ
    J Urol; 2022 Feb; 207(2):417-423. PubMed ID: 34544265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoking and lower urinary tract symptoms in Reduction by Dutasteride of Prostate Cancer Events Trial.
    Kramer JJ; Gu L; Moreira D; Andriole G; Freedland SJ; Csizmadi I
    Prostate; 2023 Jul; 83(10):990-997. PubMed ID: 37070723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study.
    Fukuta F; Masumori N; Mori M; Tsukamoto T
    BJU Int; 2012 Oct; 110(7):1023-9. PubMed ID: 22233355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there any association between the severity of lower urinary tract symptoms and the risk of biopsy-detectable prostate cancer in patients with PSA level below 20 ng/ml in multi-core prostate biopsy?
    Oh JJ; Jeong SJ; Jeong CW; Byun SS; Hong SK; Choe G; Lee SE
    Prostate; 2013 Jan; 73(1):42-7. PubMed ID: 22585359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
    Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population.
    Park JS; Koo KC; Kim HK; Chung BH; Lee KS
    Medicine (Baltimore); 2019 Oct; 98(42):e17635. PubMed ID: 31626149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study.
    He LY; Zhang M; Chen ZW; Yuan JL; Ye DW; Ma LL; Wei H; Yang JG; Chen S; Wan B; Xia SJ; Weng ZL; Kong XB; Wei Q; Jin FS; Zhang XH; Qian WQ; Wang SS; Chen YH; Ma HS; Sun YH; Gao X
    BMC Urol; 2018 Mar; 18(1):23. PubMed ID: 29587718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
    J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.